FDA approves Ogivri (Herceptin FoB) from MYL/Biocon: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm587378.htm Note: MYL has two global FoB partnerships: one with Biocon (#msg-39119393) and one with MNTA (#msg-119689602).